Palisading neutrophilic granulomatous dermatitis in a Japanese patient with Wegener's granulomatosis.
Wegener's granulomatosis (WG) is an etiologically obscure entity with multiple systemic manifestations. Recently, cytoplasmic anti-neutrophil cytoplasmic antibody (C-ANCA) has become recognized as a valuable adjunct in the diagnosis of this disorder. WG typically involves the upper airway, lungs, and kidneys, but any other organ can be involved, including the skin. We encountered a unique case in which a 27-year-old Japanese man with WG presented with various typical cutaneous manifestations. Purpuric skin lesions and erythematous rash on the lower extremities progressively involved and changed into a necrotizing ulceration on his toe. Additionally, several nodules developed on the extensor surfaces of his elbows. His serum C-ANCA level increased remarkably. Leukocytoclastic vasculitis, the most common histopathological finding in WG patients, was detected in a purpuric lesion on his hand. A biopsy of a nodule on his elbow revealed palisading epithelioid histiocyte granulomas with features of leukocytoclastic vasculitis. The distinctive pattern of papules has been referred to as "palisading neutrophilic granulomatous dermatitis". An open lung biopsy confirmed WG with focal necrotizing granuloma. A renal biopsy demonstrated necrotizing vasculitis and crescentic glomerulonephritis. He showed a good response to oral corticosteroids and cyclophospamide with total remission of symptoms. We believe that a careful balance between the clinical manifestations and the histopathological evidence allows for timely treatment of WG, which may prevent serious morbidity or death. Although uncommon, WG can present with various types of accompanying cutaneous lesions. Therefore, clinicians should keep this diagnosis in mind when presented with these manifestations.
Kawakami
Tamihiro
T
Department of Dermatology, St. Marianna University School of Medicine, Kawasaki, Japan.
Obara
Wataru
W
Soma
Yoshinao
Y
Mizoguchi
Masako
M
D000328:Adult; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000276:immunology*; D001707:Biopsy, Needle; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D006099:Granuloma / Q000150:complications / Q000175:diagnosis / Q000473:pathology* / Q000628:therapy; D014890:Granulomatosis with Polyangiitis / Q000150:complications / Q000276:immunology / Q000473:pathology* / Q000628:therapy; D006801:Humans; D007150:Immunohistochemistry; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007564:Japan; D008297:Male; D009504:Neutrophils / Q000473:pathology*; D018570:Risk Assessment; D012720:Severity of Illness Index; D013908:Thoracotomy; D016896:Treatment Outcome; D018366:Vasculitis, Leukocytoclastic, Cutaneous / Q000150:complications / Q000175:diagnosis / Q000276:immunology / Q000473:pathology* / Q000628:therapy
D019268:Antibodies, Antineutrophil Cytoplasmic; D007166:Immunosuppressive Agents